GLPwatch
Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
Cardiol Clin · 2019
Last updated 2026-05-28New diabetes drugs like empagliflozin (taken by mouth) and liraglutide (injected) have been shown in recent trials to reduce major heart-related events by 14% and 22% respectively, compared to a placebo. These benefits were larger than expected based on their effects on blood sugar control alone.
AI summary of the abstract below.
| Journal | Cardiol Clin, 2019 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.05 |
| NIH percentile | 5 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
Diabetes is a major risk factor for cardiovascular disease, yet until now treatments for diabetes had only a modest impact on cardiovascular events. New interventions for patients with type 2 diabetes mellitus (oral empagliflozin and injectable liraglutide) are associated with unprecedented reductions in composite cardiovascular outcomes that seem disproportionate to the impact on glycated hemoglobin. This review examines in detail the recent trials that arrived at these conclusions, limitations of these studies, and how these outcomes may influence patient management in the future.
Verbatim abstract via PubMed 31279427 ↗